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Cancer cells metabolize glucose by aerobic glycolysis, a phenomenon known as the Warburg
effect. Fang et al. (2010) show that the endoplasmic reticulum enzyme ENTPD5 promotes ATP
consumption and favors aerobic glycolysis. The findings suggest that nutrient uptake in cancer
cells is limited by ATP and satisfies energy requirements other than ATP production.Mounting evidence suggests that cancer
cells engage in a unique metabolic pro-
gram that allows for rapid cell prolifera-
tion. Nonproliferating cells can use glycol-
ysis products to generate ATP for their
energy needs. Such cells generally have
low rates of glycolysis followed by
oxidation of pyruvate in the mitochondria,
leading to efficient generation of ATP.
Dividing cells, in contrast, also use glycol-
ysis intermediates for the synthesis of
macromolecules and must therefore
balance their ATP requirements and
biosynthetic needs (Vander Heiden et al.,
2009). Metabolism of glucose by aerobic
glycolysis, a phenomenon known as the
Warburg effect, may help dividing cells
strike this balance.
The phosphoinositide 3-kinase (PI3K)
signaling pathway, which is activated in
many cancers, regulates cell growth and
survival. PI3K signaling has been impli-
cated in the altered glucose metabolism
of cancer cells, and the serine/threonine
kinase AKT, a major PI3K effector,
promotes glucose uptake and increases
the activity of glycolytic enzymes (DeBer-
ardinis et al., 2008). In this issue of Cell,
Fang et al. (2010) report an important
mechanism by which AKT signaling leads
to increased aerobic glycolysis. They
showthatAKTactivationpromotesprotein
glycosylation in the endoplasmic retic-
ulum, which elevates ATP consumption
and derepresses a rate-limiting enzyme
in glycolysis that is otherwise inhibited by
an elevated ratio of ATP to AMP. This
work suggests how proliferating cells
may integrate growth signals with energy
status to enable increased glucose uptake
to support cell proliferation.Activation of the PI3K pathway in
cancer can occur via genetic alterations
that allow growth factor-independent
kinase activation or via the loss of PTEN,
a lipid phosphatase that attenuates PI3K
signaling. Fang et al. now find that cell
extracts from PTEN-deficient cells have
an enhanced ability to generate AMP
from ATP. Subsequent purification and
biochemical characterization of this
activity led to the identification of ectonu-
cleoside triphosphate diphosphohydro-
lase 5 (ENTPD5) as the enzyme associ-
ated with the ATP hydrolysis activity.
PI3K signaling leads to upregulation of
ENTPD5, a UDPase that promotes the
N-glycosylation and folding of glycopro-
teins in the ER by hydrolyzing UDP to
UMP (Trombetta and Helenius, 1999)
(Figure 1). UDP hydrolysis in the ER is
a reaction necessary to promote protein
folding via the calnexin/calreticulin
pathway. It is linked to ATP hydrolysis in
the cytosol by a cycle of glucose and
phosphate transfer reactions. As part
of this cycle, the UDP-glucose/UMP anti-
porter exports UMP out of the ER in
exchange for importing UDP-glucose
into the ER (Hirschberg et al., 1998). The
UGGT enzyme then uses UDP-glucose
to transfer glucose to proteins in the ER
(Vembar and Brodsky, 2008). This
glucose addition to nascent glycoproteins
is necessary for their calnexin/calreticulin-
mediated protein folding. Thus, disruption
of ENTPD5 in PTEN-deficient cells results
in decreased protein N-glycosylation and
causes ER stress.
Cell surface proteins, including many
growth factor receptors, are N-glycosy-
lated. Fang et al. show that disruption ofCell 143, NENTPD5 leads to decreased levels of
several growth factor receptors, including
epidermal growth factor receptor (EGFR),
insulin-like growth factor receptor
b (IGFR-b), and Her2/ErbB2. Given that
growth factor signaling plays an important
role in increasing nutrient metabolism in
rapidly proliferating cells (DeBerardinis
et al., 2008), these new findings suggest
that cellular ATP levels can influence the
folding and expression of growth factor
receptors, perhaps ensuring that cells do
not attempt to grow when ATP is limiting.
Furthermore, because glucose metabo-
lism by the hexosamine biosynthesis
pathway provides the carbon for these
receptor glycosylation events, the avail-
ability of glucose may provide a means
to couple nutrient levels with growth
factor receptor expression. These feed-
backs may exist to prevent a metabolic
catastrophe caused by activation of the
cell growth machinery when the supply
of nutrients or ATP is limiting.
How does ENTPD5 regulate ATP
levels? Fang et al. find that reconstitution
of the ATP consuming activity also
requires the presence of UMP/CMP
kinase-1 and adenylate kinase-1. UMP/
CMP kinase-1 catalyzes the rephosphor-
ylation of the UMP generated by ENTPD5
into UDP (Figure 1), in the process con-
verting ATP to ADP. Adenylate kinase-1
then converts ADP molecules into ATP
and AMP, thus allowing the cycle to
continue. Surprisingly, this cycle involving
ENTPD5 is a major source of ATP
consumption in PTEN-deficient cells.
Furthermore, these reactions directly
affect the cell’s glycolytic rate. Whereas
increased ENTPD5 expression has noovember 24, 2010 ª2010 Elsevier Inc. 669
Figure 1. ENTPD5 Promotes Glycolysis in Proliferating Cells
Fang et al. (2010) show that the endoplasmic reticulum (ER) UDPase ectonucleoside triphosphate
diphosphohydrolase 5 (ENTPD5) is expressed in response to phosphoinositide 3-kinase (PI3K) signaling.
Activation of PI3K results in FOXO phosphorylation by AKT and loss of ENTPD5 transcriptional repres-
sion. This leads to increased ENTPD5 enzyme activity in the ER, promoting protein folding. ENTPD5
activity promotes the import of UDP-glucose into the ER, where UGGT transfers glucose to an unfolded
N-glycoprotein and produces UDP. Properly folded N-glycoproteins, such as growth factor receptors,
exit the cycle, whereas unfolded proteins undergo further folding attempts or are degraded. ENTPD5
activity enables this process by hydrolyzing UDP to provide the UMP necessary for exchange with
UDP-glucose in the cytosol. The activities of UMP/CMP kinase-1 and adenylate kinase-1 couple the
energetic requirements of this cycle to the net conversion of ATP to AMP. Thus, increased ENTPD5
activity leads to a decrease in the cellular ATP/AMP ratio. Because this ratio is the major determinant
of glucose flux through the phosphofructokinase (PFK) step in glycolysis, a lowered ATP/AMP ratio
increases glycolysis, elevates lactate production, and provides glycolytic intermediates for biomass
production.effect on cellular respiration, it increases
lactate production, suggesting a link
between ATP consumption and in-
creased glycolytic flux. In a series of
experiments to determine how ENTPD5
increases glucose entry into glycolysis,
Fang et al. find that the ratio of fructose-
6-phosphate to fructose-1-6-bisphos-
phate increases in cells following ENTPD5
knockdown, consistent with inhibition of
this step in glycolysis. Phosphofructoki-
nase (PFK), the enzyme that catalyzes
this reaction, is the major enzyme control-
ling glucose commitment to the glycolytic
pathway (Dunaway, 1983). A high ATP/
AMP ratio in the cell inhibits both PFK
activity and glucose metabolism by
glycolysis. In fact, the authors conclude
that increased ATP consumption by
ENTPD5 increases glycolysis by lowering
the ATP/AMP ratio and relieving allosteric
inhibition of PFK.670 Cell 143, November 24, 2010 ª2010 ElseATP is likely not the growth-limiting
resource for most cells (Vander Heiden
et al., 2009). The concept that glucose
utilization by tumor cells may be limited
by ATP consumption to prevent feedback
inhibition of PFK has been suggested
previously (Scholnick et al., 1973). This
study finally provides a mechanism by
which cells can increase ATP consump-
tion to drive glucose uptake. An additional
mechanism has also recently been
described in which glucose incorporation
into biosynthetic pathways occurs
without producing excess ATP (Vander
Heiden et al., 2010). Together, these
studies support the notion that altered
metabolism in cancer is not adapted to
support ATP production.
Fang et al. show that ENTPD5 expres-
sion correlates with PI3K activation in
human prostate cancer cell lines and
tumor tissue samples. Not all cancer cellsvier Inc.are dependent on activated PI3K, sug-
gesting that increased ENTPD5 activity
may not be a universal mechanism for
lowering ATP levels in tumors. However,
other enzymes involved in regulating
nucleotide pools in cells have also been
linked to cancer (Hartsough and Steeg,
2000), and there are additional homologs
of ENTPD5 whose functions are not well
understood. These enzymes may be
involved in analogous cycles of ATP con-
sumption, leading to enhanced glucose
metabolism in other genetic contexts.
Fang et al. also show that decreased
ENTPD5 expression inhibits tumor
growth, possibly via pleiotropic effects
involving induction of ER stress and
altered glucose metabolism. Consider-
ation of ENTPD5 as a potential thera-
peutic target in PI3K-driven cancer is
interesting given that pharmacological
inhibition of ENTPD5 is predicted to
decrease tumor ATP consumption.
Although counterintuitive, the resulting
increase in ATP/AMP ratio might reduce
the entry of glucose into glycolysis and
starve the cells of precursors necessary
for biosynthesis. Successful efforts to
target cancer metabolism will likely arise
from understanding the feedbacks and
complex regulation that are required for
anabolic metabolism. The study by Fang
et al. provides new insight by demon-
strating that ATP consumption serves to
increase glucose flux to satisfy the ener-
getic and biosynthetic demands of
a rapidly proliferating cell.
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